Technical Analysis for RCKT - Rocket Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 27.49 -3.85% -1.10
RCKT closed down 3.85 percent on Friday, August 14, 2020, on 70 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical RCKT trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -3.85%
New 52 Week High Strength -3.85%
Upper Bollinger Band Walk Strength -3.85%
Above Upper BB Strength -3.85%
Overbought Stochastic Strength -3.85%
Upper Bollinger Band Touch Strength -3.85%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Medicine Biotechnology Heart Failure Anemia University Of California Fanconi Anemia Genetic Disorder Pyruvate Kinase Deficiency

Is RCKT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.14
52 Week Low 9.01
Average Volume 460,795
200-Day Moving Average 19.79
50-Day Moving Average 23.00
20-Day Moving Average 25.71
10-Day Moving Average 26.61
Average True Range 1.60
ADX 32.44
+DI 27.44
-DI 12.66
Chandelier Exit (Long, 3 ATRs ) 24.35
Chandelier Exit (Short, 3 ATRs ) 27.93
Upper Bollinger Band 28.44
Lower Bollinger Band 22.98
Percent B (%b) 0.83
BandWidth 21.22
MACD Line 1.33
MACD Signal Line 1.17
MACD Histogram 0.1599
Fundamentals Value
Market Cap 742.56 Million
Num Shares 27 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -17.97
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.79
Resistance 3 (R3) 30.89 29.90 30.24
Resistance 2 (R2) 29.90 29.06 29.85 30.06
Resistance 1 (R1) 28.69 28.54 28.20 28.59 29.87
Pivot Point 27.70 27.70 27.45 27.65 27.70
Support 1 (S1) 26.49 26.86 26.00 26.39 25.11
Support 2 (S2) 25.50 26.34 25.45 24.92
Support 3 (S3) 24.29 25.50 24.74
Support 4 (S4) 24.19